RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions

INTRODUCTION: Mutations in KRAS and NRAS genes are negative predictors of anti-EGFR therapies response in metastatic colorectal cancer. There are few reports on RAS testing in synchronous primary colorectal cancer (SP-CRC) and a lack of recommendations on which tissue should be tested for the mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: de Macedo, Mariana Petaccia, de Melo, Fernanda Machado, Ribeiro, Júlia da Silva, de Mello, Celso Abdon Lopes, de Souza Begnami, Maria Dirlei Ferreira, Soares, Fernando Augusto, Carraro, Dirce Maria, da Cunha, Isabela Werneck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381705/
https://www.ncbi.nlm.nih.gov/pubmed/25859555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381705/
https://www.ncbi.nlm.nih.gov/pubmed/25859555

Ejemplares similares